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Looking for Needles in the Plasmodial Haystack
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ABSTRACT Plasmodium falciparum malaria remains a globally leading infectious dis-
ease problem. Despite decades of intense investigation, an efﬁcacious and practical
vaccine offering durable protection to people living in areas with transmission of
malaria parasites remains an elusive goal. Our fragmentary understanding of the
mechanisms of protective immunity to the disease is a major obstacle, and the al-
most complete focus on a very small subset of P. falciparum proteins as vaccine can-
didates has left most parasite antigens essentially unexplored as targets of acquired
immunity. However, with the protein microarray technology, it is now possible to in-
terrogate the entire parasite proteome for new vaccine candidates and for markers
of parasite exposure. Recent mSphere papers describe the results of such research.
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THE MALARIA PROBLEM
The most serious form of malaria, caused by the hemoprotozoan parasite Plasmo-dium falciparum, is a major cause of human suffering and death, not least in
equatorial Africa. Although the number of cases has decreased steadily over the last
decade, the pace is ﬂagging, and the disease burden remains completely unacceptable
(1). Continued progress toward eliminating and ultimately eradicating malaria is threat-
ened by drug resistance, insecticide resistance, and other problems. An efﬁcacious
vaccine that is suitable for mass administration and that ideally induces durable
protection after a few immunizations would be a major game changer. Indeed, such a
vaccine has been the holy grail of malaria immunology research for decades. Regret-
tably, the reward of this eager pursuit has been meager, and the only malaria vaccine
licensed so far affords only partial and short-term protection. One limitation of the
vaccine development efforts has been the dogged focus on a few antigens (WHO,
Malaria Vaccine Rainbow Tables [http://www.who.int/vaccine_research/links/Rainbow/
en/index.html; accessed 26 February 2019]).
THE PLASMODIAL HAYSTACK
Most of the current vaccine candidates were discovered many years ago and
showed promise in initial work, but many are still backed by less than rock solid
evidence that they are in fact key targets of protective immunity against P. falciparum
malaria in humans.
In areas with stable parasite transmission, clinical immunity to P. falciparum malaria
is acquired in a piecemeal manner over several years and after many infections and
disease episodes. It is paralleled by acquisition of antibodies to many of the approxi-
mately 5,300 proteins encoded by the parasite (2). Suspected protective antigens may
thus, in reality, be covariates of genuinely protective antigens, and separating the
wheat from the chaff in this enormous plasmodial haystack has proved very difﬁcult.
The task is further complicated by the fact that many P. falciparum antigens are highly
polymorphic and/or clonally variant. Finally, we cannot even be certain that there is
indeed a particular immune response targeting a particular epitope in a particular
antigen that mediates protection across the board.
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FINDING THE NEEDLE(S) IN THE HAYSTACK
Given the uncertainty that any of the relatively few antigens investigated thoroughly
so far really holds the solution to the vaccine challenge—the needle in the above-
mentioned haystack—it seems obvious to widen the portfolio of candidates. Until fairly
recently, technology has seriously limited the practicality of comprehensive screening
for novel clinically important candidates, but that may be about to change. The authors
of a recent report in mSphere (3) thus combined the remarkable ability of controlled
human malaria infection (CHMI) to induce protective immunity (4) with the possibility
of identifying important antibody reactivities mediating it, by employing large protein
arrays including thousands of antigens (5). The analysis by Obiero et al. (3) of an array
covering more than 90% of the P. falciparum proteome revealed that in some individ-
uals CHMI induced antibody responses to only a few antigens (low responders), broader
and higher responses in others (medium responders), and high responses to many
antigens in yet other CHMI recipients (high responders). Remarkably, essentially all low
and high responders were clinically protected from challenge infection, suggesting that
clinical protection can be achieved in different ways in different individuals, even when
exposed to infection in exactly the same way. However, the authors focused on the
moderate responder group, which contained most of the nonprotected individuals but
also several who were protected. Analysis of the antibody responses among susceptible
versus protected moderate responders allowed the authors to identify small subsets of
antibody speciﬁcities associated with either status. Perhaps even more remarkable was
the ﬁnding that the six protective antigens did not include any current vaccine
candidate, whereas four of the six susceptibility markers belonged to members of the
P. falciparum EMP1 (PfEMP1) family that have otherwise been implicated as important
mediators of clinical protection after natural exposure (6). The study by Obiero et al. (3)
thus illustrates the great potential of brute-force studies not only for identifying new
vaccine candidates (“needles”) but also for inadvertently increasing the size of the
plasmodial haystack to be sifted. More focused traditional follow-up studies are un-
doubtedly needed to conﬁrm or refute the validity of the candidates identiﬁed by
hypothesis-free approaches, such as the one used by Obiero et al. (3), and to delineate
plausible protective mechanisms of promising antibody speciﬁcities. Hybrids between
the new hypothesis-free all-encompassing approach and the traditional, hypothesis-
driven single/few-antigen approaches might offer an interesting compromise. The
KILchip merozoite antigen array (7) and the PfEMP1/RIFIN/STEVOR array (8) are exam-
ples of this.
SEVERAL TYPES OF NEEDLES
The study of Obiero et al. (3) also illustrates another interesting point. Although
particular antibody responses are not directly related to clinical protection, they can
nevertheless sometimes be used as markers of short-term or long-term changes in
exposure. Such responses can therefore be convenient tools to map malaria endemicity
and to monitor the efﬁcacy of interventions. Relevant antibody speciﬁcities for this task
constitute a class of antigenic “needles” different from those discussed above and,
arguably, one easier to ﬁnd, not least by big antigen arrays, obviously so not only
because of their comprehensiveness but also because ﬁdelity in the reproduction of
particular native epitopes is likely to be less of a concern than when looking for the
targets of protective antibodies. In another recent mSphere report (9), Kobayashi et al.
used a 500-exon array to analyze serum samples collected in various surveys at sites
with different transmission intensities and patterns in southern Africa. While falling
short of identifying a one-size-ﬁts-all set of exposure markers, the study demonstrated
important age- and transmission intensity-dependent qualitative and quantitative dif-
ferences in antibody responses, similar to ﬁndings from previous studies (10–12).
Furthermore, the study supports the idea that acquisition of protective immunity to
malaria involves not only increases in antibody quantity and quality but also a gradual
shift from predominantly transient responses in childhood to more sustained responses
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in adults, as proposed previously (13). Such a transition may be an important reﬂection
of how immunological memory to malaria is induced and maintained.
CONCLUDING REMARKS
Antigen arrays of steadily increasing comprehensiveness and quality are becoming
powerful tools in the analysis of acquired immunity to P. falciparum malaria. The recent
mSphere reports (3, 9) are good examples of this. Big antigen arrays clearly have the
potential to help us identify sorely needed new and clinically decisive antigenic targets.
However, if not used carefully—and probably best in conjunction with other, lower-
throughput but more in-depth approaches—they may also generate a considerable
number of false leads. We should certainly use these tools (we need all the help we can
get) but must take care to use them wisely.
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